Silk fibroin nanoparticles enhance quercetin immunomodulatory properties in DSS-induced mouse colitis
Metadatos
Mostrar el registro completo del ítemAutor
Díez Echave, Patricia; Ruiz Malagón, Antonio Jesús; Molina Tijeras, José Alberto; Hidalgo García, Laura; Vezza, Teresa; Cenis Cifuentes, Laura; Rodríguez Sojo, María Jesús; Cenis, José Luis; Rodríguez Cabezas, María Elena; Rodríguez Nogales, Alba; Gálvez Peralta, Julio Juan; Lozano-Pérez, Antonio AbelEditorial
Elsevier
Materia
Inflammatory bowel disease Silk fibroin nanoparticles Quercetin Anti-inflammatory Drug loading
Fecha
2021-09-05Referencia bibliográfica
P. Diez-Echave et al. Silk fibroin nanoparticles enhance quercetin immunomodulatory properties in DSS-induced mouse colitis. International Journal of Pharmaceutics 606 (2021) 120935. [https://doi.org/10.1016/j.ijpharm.2021.120935]
Patrocinador
European Commission ERDF/FEDER Operational Programme `Murcia' CCI 2007ES161PO001- 14-20/20; Junta de Andalucia CTS164; Instituto de Salud Carlos III European Commission PI19/01058; Spanish MINECO CTQ201787708-R; ERDF/FEDER Operational Programme 'Murcia' CCI 2007ES161PO001- 14-20/20Resumen
Inflammatory bowel disease (IBD) is a chronic and idiopathic inflammatory disorder affecting the gastrointes-tinal tract. The pharmacological treatments used currently for its treatment lack efficacy, so new therapeutic strategies should be developed. In this context, flavonoids loaded in biopolymeric nanoparticles can be considered as novel promising candidates. The aim of the present study was to evaluate the intestinal anti-inflammatory effects of quercetin when is administered loaded in silk fibroin nanoparticles (QSFN) in the dextran sulphate sodium experimental model of mouse colitis, which displays some similarities to human IBD. Previously characterized quercetin-loaded silk fibroin nanoparticles (QSFN). QSFN showed a reversible aggre-gation profile induced by the acidification of the solution but did not affect the loaded quercetin. Daily administration of QSFN significantly reduced disease activity index values compared to the control colitic group. This beneficial effect was not only corroborated by the histological examination of the colonic specimens but also the improvement of the colonic expression of the different proinflammatory cytokines (Tnf-alpha, Il-1 beta, Il-6, Mcp-1, Icam-1, Nlrp3 and iNOS). Therefore, these data suggest that QSFN could be a promising alternative to current treatments as a drug delivery system for IBD treatment.